Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's and General Mills saw declines. However, some food stocks like Kraft Heinz and Hershey have shown gains this year, and ETFs tracking food and pharmaceuticals reveal a more nuanced picture than the broad "food so hated" label suggests. Investors should be cautious as the GLP-1 impact remains uncertain, and some food stocks are recovering, indicating the sentiment gap may be closing rather than presenting a clear buying opportunity.
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
J.P. Morgan Life Sciences Private Capital has named Bruce N. Rogers, Ph.D., as a Venture Partner. Dr. Rogers brings extensive experience in drug discovery and development, having led significant roles at Morphic Therapeutic and Pfizer. His expertise ...
Three major large-cap growth ETFs—Schwab SCHG, Vanguard VUG, and Invesco QQQ—offer different approaches to capturing growth, especially in AI and tech sectors. QQQ, tracking the Nasdaq-100, outperformed with a 10-year return of about 513%, benefiting...
